Oramed Pharmaceuticals (ORMP) Cash from Operations (2010 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Cash from Operations came in at 2915000.0 in Q1 2026, up 17.16% YoY from 2487966.29 in Q1 2025, and down 525.54% on a QoQ basis from 466000.0 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Cash from Operations (2010 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 17 years of Cash from Operations data on file, last reported at 2915000.0 in Q1 2026.
- Quarterly Cash from Operations rose 17.16% year-over-year to 2915000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 8541000.0 (up 18.31% YoY) and the FY2025 annual result came in at 9145000.0, down 8.71% from the prior year.
- Cash from Operations fell to 2915000.0 in Q1 2026, from 466000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 2076000.0 in Q2 2024 to a low of 9125000.0 in Q1 2022.
- A 5-year average of 3452058.82 and a median of 2634000.0 in 2023 frame the typical range for Cash from Operations.
- The widest YoY moves for Cash from Operations: up 178.82% in 2024, down 923.2% in 2024.
- Tracing ORMP's Cash from Operations over 5 years: stood at 8062000.0 in 2022, then soared by 82.41% to 1418000.0 in 2023, then tumbled by 34.77% to 1911000.0 in 2024, then surged by 75.61% to 466000.0 in 2025, then slumped by 525.54% to 2915000.0 in 2026.
- The last three Cash from Operations figures came in at 2915000.0 (Q1 2026), 466000.0 (Q4 2025), and 1625000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Oramed Pharmaceuticals | 196.17 Mn | 196.17 Mn | - | -200,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -200,000.00 |
| Jun 30, 2026 | -200,000.00 |
| Mar 31, 2026 | -2.92 Mn |
| Mar 31, 2026 | -2.92 Mn |
| Dec 31, 2025 | -466,000.00 |
| Dec 31, 2025 | -466,000.00 |
| Sep 30, 2025 | -1.63 Mn |
| Sep 30, 2025 | -1.63 Mn |
| Jun 30, 2025 | -3.54 Mn |
| Jun 30, 2025 | -3.54 Mn |
| Mar 31, 2025 | -3.52 Mn |
| Mar 31, 2025 | -3.52 Mn |
| Dec 31, 2024 | -1.91 Mn |
| Dec 31, 2024 | -1.91 Mn |
| Sep 30, 2024 | -7.10 Mn |
| Sep 30, 2024 | -7.10 Mn |
| Jun 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 2.08 Mn |
| Mar 31, 2024 | -1.48 Mn |
| Mar 31, 2024 | -1.48 Mn |